This study aims at identification of the effect of fingolimod on expanded disability status scale (EDSS) score and number of relapses in relapsing-remitting MS (RRMS) patients in comparison with IFNβ. This evidence concerns the gene IFNB1 and relapsing-remitting multiple sclerosis.